Cancer Immunotherapeutic GSK1572932A as Adjuvant Therapy for Patients With MAGE-A3-Positive Non-Small Cell Lung Cancer.

Trial Profile

Cancer Immunotherapeutic GSK1572932A as Adjuvant Therapy for Patients With MAGE-A3-Positive Non-Small Cell Lung Cancer.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Zastumotide (Primary) ; Cisplatin; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms MAGE3-AS15-NSC-001 (ADJ-Chemo)
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 08 Jun 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 13 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top